Scientists decode genetic clues in rare bone marrow cancer

NCT ID NCT05710211

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how specific genetic changes (ASXL1 mutations) affect the course of myelofibrosis, a rare bone marrow cancer. Researchers will analyze blood and bone marrow samples from 50 adults to identify different patterns of these mutations. The goal is to better predict how the disease will progress and guide future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

AP-HP Hôpital Saint Louis
NOT_YET_RECRUITING

Paris, 75010, France
CH Cholet
NOT_YET_RECRUITING

Cholet, France
CH de Cornouaille
NOT_YET_RECRUITING

Quimper, France
CH de Vannes
NOT_YET_RECRUITING

Vannes, France
CHRU Brest
NOT_YET_RECRUITING

Brest, France
CHRU Tours - Hôpital Bretonneau
RECRUITING

Tours, France
CHU Angers
RECRUITING

Angers, France
CHU Henri MONDOR
RECRUITING

Créteil, 94010, France
CHU Lyon
RECRUITING

Pierre-Bénite, 69495, France
CHU Nantes
NOT_YET_RECRUITING

Nantes, France
CHU de Bordeaux
RECRUITING

Pessac, 33604, France
Hôpital Bicêtre
RECRUITING

Paris, France
Institut Paoli Calmettes
RECRUITING

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.